$WHWK News

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Whitehawk Therapeutics Enters PIPE Financing With Expected Gross Proceeds Of ~$87.5M From Sale Of 4,330,866 Shares At $3.92 Per Share And Warrants To Purchase 17,991,021 Shares At $3.9199 Per Warrant

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics Q1 EPS $(0.32) Misses $(0.09) Estimate

Reported Sunday, Whitehawk Therapeutics Presents Preclinical Data For HWK-007, HWK-016 And HWK-206 Next-Generation ADC Portfolio At AACR 2026, Showing Tumor Regressions At Low Single-Digit Mg/Kg Doses

Whitehawk Therapeutics shares are trading higher after Citizens initiated its coverage on the stock with a Market Outperform rating and announced a price target of $8.